What are the current guidelines for HPV testing during Pap smear cervical cancer screening?

HPV and Pap Smear Screening Guidelines

Begin cervical cancer screening at age 25 with primary HPV testing every 5 years as the preferred strategy; continue through age 65 unless adequate negative screening is documented. 1, 2

Screening Strategy by Age

Ages <21 Years

• Do not screen regardless of sexual history or risk factors 2

Ages 21-24 Years

• Cytology (Pap smear) alone every 3 years 2
• Never use HPV testing (stand-alone or cotesting) in this age group—approximately 21% have transient HPV infections that lead to unnecessary follow-up and potential overtreatment 2
• This age group accounts for only 0.8% of cervical cancer cases 2
• Screening before age 25 increases risk of adverse obstetric outcomes from unnecessary treatment of lesions that would spontaneously regress 2

Ages 25-65 Years (Primary Screening Period)

Preferred Strategy:

• Primary HPV testing every 5 years 1, 2
• Only 2 FDA-approved primary HPV tests are currently available for stand-alone screening, both approved starting at age 25 1, 2

Acceptable Alternatives (transitional options being phased out):

• Cotesting (HPV + cytology) every 5 years 1, 2
  • Provides highest sensitivity among screening modalities 2
  • Negative cotest confers 5-year cumulative risk of CIN2+ of only 0.34% 2
  • Improves detection of adenocarcinoma precursors 2
• Cytology alone every 3 years when HPV testing unavailable 1, 2

The American Cancer Society explicitly states that cotesting and cytology-alone options will be phased out as the U.S. completes transition to primary HPV testing 2

Ages >65 Years

• Discontinue all screening if adequate negative prior screening documented 1, 2
• Never resume screening after cessation, even with new sexual partners 2

Criteria to Stop Screening at Age 65

Must meet BOTH requirements:

1. Adequate negative screening (any one of the following within past 10 years, most recent within 5 years):

   • 2 consecutive negative primary HPV tests, OR 1, 2
   • 2 consecutive negative cotests, OR 1, 2
   • 3 consecutive negative cytology results 1, 2

2. No history of CIN2+ in the preceding 25 years 1, 2

Updated 2026 Exit Criteria: The American Cancer Society now recommends negative primary HPV tests (preferred) or negative cotesting at both ages 60 AND 65 years as a requisite to exit screening, with the last test at age no younger than 65 3

Critical Exceptions Requiring Modified Screening

Population	Recommendation	Citation
HIV-positive or immunocompromised	Annual screening regardless of age	[2]
Organ transplant recipients	Annual screening	[2]
Chronic systemic corticosteroids	Annual screening	[2]
Ongoing chemotherapy	Annual screening	[2]
History of CIN2, CIN3, or AIS	Continue screening for 20-25 years after treatment, even beyond age 65	[1,2]
In-utero DES exposure	Follow standard age-based screening	[2]
Total hysterectomy (cervix removed, no CIN2+ or cancer history in past 25 years)	No screening required	[1,2]
Subtotal hysterectomy (cervix retained)	Follow standard age-based screening	[2]

HPV Vaccination Status

• Screening recommendations are identical for vaccinated and unvaccinated individuals 1, 2
• Current vaccines do not protect against all oncogenic HPV types 2
• Never reduce screening frequency or stop early based solely on vaccination status 2

Key Screening Principles

Why HPV Testing is Age-Restricted

• HPV testing (stand-alone or cotesting) must not be performed before age 30 in most guidelines, though ACS now recommends starting primary HPV at age 25 1, 2
• The USPSTF issues a Grade D recommendation against HPV testing under age 30 due to high prevalence of transient infections 2

Why Annual Screening is Harmful

• Annual screening is never recommended with any method 2
• Average progression time from high-grade precancer to invasive cancer is approximately 10 years, justifying extended intervals 2
• More frequent screening provides minimal additional benefit but substantially increases false-positives, unnecessary colposcopies, overtreatment, and adverse obstetric outcomes 2

Self-Collection Option (2026 Update)

• Self-collected vaginal specimens for HPV testing are acceptable for average-risk individuals aged 25-65 when clinician-collected specimens are not feasible 3
• Clinician-collected cervical specimens remain preferred 3
• Self-collected specimens require 3-year screening interval (not 5-year) after negative result 3
• Only FDA-approved combinations of collection devices and HPV assays may be used 3

Management of Abnormal Results

• All abnormal results should be managed according to the 2019-2020 ASCCP Risk-Based Management Guidelines 1, 2
• Immediate colposcopy indicated for high-grade squamous intraepithelial lesion (HSIL) 2
• Timely follow-up and treatment of abnormal results yields greatest reduction in cervical cancer incidence and mortality 2

Common Pitfalls to Avoid

• Never discontinue screening at age 65 without verifying adequate prior negative screening through medical records—verbal patient report is insufficient 2
• Never use HPV testing in women under age 30 (except for primary HPV screening starting at age 25 per ACS) 2
• Never screen individuals under age 21 regardless of sexual history 2
• Never continue using cytology alone or cotesting when primary HPV testing is available—these are transitional strategies being phased out 1, 2

Pregnancy Considerations

• Screening recommendations apply to pregnant individuals with intact cervix 2
• Pregnancy does not alter recommended age-based intervals or methods 2